Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses
Despite the fact that the new drugs and targeted therapies have been approved for cancer therapy during the past 30 years, the majority of cancer types are still remain challenging to be treated. Due to the tumor heterogeneity, immune system evasion and the complex interaction between the tumor micr...
Main Authors: | Mahdie Jafari, Maryam Kadkhodazadeh, Mina Bahrololoumi Shapourabadi, Nasser Hashemi Goradel, Mohammad Ali Shokrgozar, Arash Arashkia, Shahriyar Abdoli, Zahra Sharifzadeh |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1012806/full |
Similar Items
-
Improving immunovirotherapies: the intersection of mathematical modelling and experiments
by: Christine E. Engeland, et al.
Published: (2022-06-01) -
Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option
by: Sweety Asija, et al.
Published: (2023-03-01) -
Development of a New Hyaluronic Acid Based Redox-Responsive Nanohydrogel for the Encapsulation of Oncolytic Viruses for Cancer Immunotherapy
by: Siyuan Deng, et al.
Published: (2021-01-01) -
Cytotoxic effect of dual fluorescent-labeled oncolytic herpes simplex virus type 1 on mouse tumorigenic cell lines
by: Shahriyar Abdoli, et al.
Published: (2019-01-01) -
Oncolytic Adenoviruses in Cancer Treatment
by: Ramon Alemany
Published: (2014-02-01)